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Abstract Many Mendelian traits are likely unrecognized owing to absence of traditional segregation
patterns in families due to causation by de novo mutations, incomplete penetrance, and/or variable
expressivity. Genome-level sequencing can overcome these complications. Extreme childhood phenotypes
are promising candidates for new Mendelian traits. One example is early onset hypertension, a rare form
of a global cause of morbidity and mortality. We performed exome sequencing of 40 unrelated subjects
with hypertension due to primary aldosteronism by age 10. Five subjects (12.5%) shared the identical,
previously unidentified, heterozygous CACNA1HM1549V mutation. Two mutations were demonstrated to be
de novo events, and all mutations occurred independently. CACNA1H encodes a voltage-gated calcium
channel (CaV3.2) expressed in adrenal glomerulosa. CACNA1HM1549V showed drastically impaired channel
inactivation and activation at more hyperpolarized potentials, producing increased intracellular Ca2+, the
signal for aldosterone production. This mutation explains disease pathogenesis and provides new insight
into mechanisms mediating aldosterone production and hypertension.
DOI: 10.7554/eLife.06315.001

Introduction
The steroid hormone aldosterone is normally produced in the adrenal zona glomerulosa in response
to either angiotensin II, which is produced in response to volume depletion, or hyperkalemia (high
plasma K+ level). Both stimuli cause membrane depolarization, activating voltage-gated Ca2+ channels;
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eLife digest The consequence of mutations to the large majority of human genes is unknown.
Most mutations that are currently known were discovered by tracing their effects through families.
This allows the locations of mutations to be pinpointed on chromosomes—the structures that
genetic material is packaged into. Other mutations are harder to trace because individuals with these
mutations may develop very different signs and symptoms, or not develop clinical abnormalities at
all. Alternatively, a trait may appear sporadically in a family because the mutation arises anew in the
affected subject.
Recently developed technologies that allow scientists to rapidly sequence all the gene-encoding
regions of an individual’s DNA—their genome—offer a new way to identify harmful genetic variants.
Comparing the genomes of individuals with rare disorders can reveal if the individuals share any
genetic mutations in common that could cause their symptoms.
Scholl et al. used this strategy to sequence the genomes of 40 individuals with a rare type of
hypertension—a condition that causes high blood pressure, and increases the risk of strokes, kidney
failure and heart attacks—that develops early in childhood. In this form of the disease, high blood
pressure is caused by the adrenal glands above the kidneys producing too much of a hormone called
aldosterone. Some genetic causes of this form of the disease have already been identified. Now,
Scholl et al. have found a new genetic mutation present in five families with this condition. Two of the
individuals were the first in their families to develop this mutation, while three others inherited it.
Some of the family members with this mutation had hypertension and some did not.
The mutation is in a gene that encodes a type of calcium channel—a protein found in the
membrane that surrounds cells, and which can open and close to control the amount of calcium in the
cell. This particular calcium channel is abundant in the cells of the adrenal gland. Scholl et al. found
that the mutation causes the calcium channels to be more likely to open and take longer to close.
This increases the number of calcium ions that move into the cell, which causes the adrenal gland to
produce more aldosterone. These new insights have provided a new way of diagnosing early-onset
hypertension, and suggest that targeting calcium channels could help to develop new treatments for
this disease.
DOI: 10.7554/eLife.06315.002

increased intracellular Ca2+ provides the signal that triggers aldosterone production (Spät and
Hunyady, 2004). In the setting of volume depletion, aldosterone signaling in renal and intestinal
epithelia produces increased salt (re)absorption, promoting restoration of intravascular volume; in
hyperkalemia, aldosterone promotes increased potassium secretion, restoring electrolyte balance.
Pathological secretion of aldosterone in the absence of normal physiological stimuli leads to
primary aldosteronism (PA), producing increased salt (re)absorption and hypertension. Hypokalemia is
a frequently associated finding, resulting from increased renal K+ elimination. PA is found in 10% of
patients referred for evaluation of hypertension (Conn, 1955; Rossi et al., 2006). About half of these
patients have adrenal aldosterone-producing adenomas (APAs). Germline mutations in three genes
have been shown to cause rare Mendelian forms of early-onset PA. Gene fusions leading to constitutive
expression of aldosterone synthase (encoded by CYP11B2), a rate-limiting enzyme in aldosterone
biosynthesis, cause Glucocorticoid-Remediable Aldosteronism (GRA) (Lifton et al., 1992).
Mutations in and near the selectively filter of the K+ channel encoded by KCNJ5 result in channels
that conduct Na+, leading to adrenal glomerulosa cell depolarization and activation of Ca2+ channels,
producing a Mendelian form of aldosteronism (Choi et al., 2011). Gain of function mutations in the
calcium channel encoded by CACNA1D cause increased Ca2+ channel activity and another form of PA.
These latter patients also have seizures, neurodevelopmental and neuromuscular abnormalities owing
to gain of function effects of CACNA1D in the nervous system (Scholl et al., 2013). Families with GRA
often have many affected subjects and were identified by linkage analysis in extended families (Lifton
et al., 1992). Germline mutations in KCNJ5 are typically de novo or in small nuclear families; similarly,
CACNA1D mutations to date are all de novo (Choi et al., 2011; Scholl et al., 2012, 2013). Germline
mutations in KCNJ5 and CACNA1D were found following identification of the same or related
somatic mutations as drivers of APAs (Choi et al., 2011; Scholl et al., 2012; Azizan et al., 2013;
Scholl et al., 2013).
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The causes of PA in many patients remain undetermined. Although Mendelian inheritance has been
suggested by recurrence of PA in some kindreds without mutations in known genes (Stowasser et al.,
1992; Torpy et al., 1998; Lafferty et al., 2000), traditional linkage analysis has failed to identify
additional causative genes, likely due to a combination of factors including locus heterogeneity, high
frequency of de novo mutations, reduced penetrance and/or variable expressivity. The advent of
next-generation sequencing, allowing the search for recurrent mutations or greater burden of rare
variants in individual genes than expected by chance, can permit identification of such loci in the
absence of classical segregation patterns. Very rare phenotypes, such as childhood PA, are promising
candidates for such traits.
Using exome sequencing, we here identify five independent occurrences of the identical mutation in
CACNA1H among 40 subjects with unexplained PA in childhood. CACNA1H encodes a voltage-gated
calcium channel that is expressed in adrenal glomerulosa. Electrophysiology demonstrates that this
variant causes reduced inactivation and a shift of activation to more hyperpolarized potentials, effects
inferred to produce increased calcium influx and PA.

Results
Whole-exome sequencing of 40 subjects with PA
From a cohort of more than 1500 unrelated subjects referred for evaluation of genetic forms of
hypertension, we identified 40 subjects diagnosed with hypertension and PA by age 10 years in whom
disease-causing mutations in CYP11B2, KCNJ5, and CACNA1D (Lifton et al., 1992; Choi et al., 2011;
Scholl et al., 2013) were excluded. Clinical details are shown in Supplementary file 1A. All subjects
had hypertension with elevated aldosterone levels despite low plasma renin activity (PRA). None of
the subjects studied were the offspring of consanguineous union. DNA from peripheral blood was
subjected to exome capture and sequencing; mean coverage was 73 independent reads per targeted
base (Supplementary file 1B). Variants were called as described in ‘Materials and methods’ (Lemaire
et al., 2013).
We performed three analyses tailored to the expectation of a rare genetic disease (‘Materials and
methods’). We sought previously unreported (absent in dbSNP, NHLBI, 1000Genomes and Yale exome
databases) protein-altering variants that occurred in more than one subject (Supplementary file 1C); we
performed gene burden analyses to search for previously unreported or rare (minor allele frequency
[MAF] < 0.01%) heterozygous variants that collectively occurred in any gene more often than expected
by chance (Supplementary file 1D); we searched for rare (MAF < 0.1%) homozygous and potential
compound heterozygous variants that collectively occurred in any genes more often than expected by
chance (Supplementary file 1E).

Identification of a recurrent novel variant in CACNA1H
There was only one result that surpassed genome-level significance: we found five apparently
unrelated subjects with the identical previously unreported heterozygous A > G variant, resulting in
a p.Met1549Val substitution in CACNA1H, which encodes the pore-forming alpha subunit of a T-type,
low voltage-activated calcium channel (aka CaV 3.2) (Figure 1, Table 1, Supplementary file 1F)
(Perez-Reyes, 2003). This variant is absent among more than 129,000 alleles sequenced from
diverse populations in the Exome Aggregation Consortium (Exome Aggregation Consortium),
and Yale databases. No other CACNA1H alleles with allele frequencies <0.01% were found
among our cohort. Like other Ca 2+ channel alpha subunits, CACNA1H contains four homologous
repeats (I–IV), each with six transmembrane segments (S1–S6). The CACNA1H M1549V variant lies
in the S6 segment of repeat III (Marksteiner et al., 2001). Sanger sequencing in each case
confirmed the heterozygous variant (Figure 1A).
Three index cases were of European ancestry, one Hispanic, and one African American by selfreport and principal component analysis (Figure 1—figure supplement 1). Members of the extended
families were recruited, and sequencing of these subjects demonstrated that CACNA1HM1549V was
a de novo mutation (absent in the biological parents) in both the index case of kindred 1347, and in
the affected mother of the index case in kindred 1390 (Figure 1). Analysis of highly polymorphic
markers confirmed paternity and maternity in both kindreds (Supplementary file 1G). This establishes
independent occurrences of CACNA1HM1549V in these two kindreds. In the remaining three kindreds,
the variant was transmitted to the index case from a parent, and samples from grandparents were not
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Figure 1. Kindreds with hypertension and primary aldosteronism (PA) with CACNA1HM1549V mutation at conserved position of S6 domain. (A) Pedigrees of
kindreds with CACNA1HM1549V mutation are shown. Studied subjects with early-onset hypertension are shown as black filled symbols, and subjects with
early-onset hypertension by family history (K333) or low renin with normal blood pressure (K1393) are shown as grey filled symbols. Genotypes are
indicated below each symbol (+/+ denotes wild type sequence; +/M denotes heterozygosity for CACNA1HM1549V variant). Corresponding Sanger
sequencing results for selected subjects are depicted to the right. (B) Transmembrane structure of CaV3.2 (encoded by CACNA1H), the pore-forming
subunit of a voltage-gated Ca2+ channel, is shown. These channels have four internal homologous repeats (I–IV), each with six transmembrane segments
(S1–S6) and a membrane-associated loop between the pore-forming S5 and S6 segments. The p.Met1549Val mutation is located in S6 of repeat III. (C)
Conservation of CACNA1HM1549 in CACNA1H orthologs and paralogs. The amino acid sequences of the S6 segment of domain III of CACNA1H, orthologs
and paralogs are shown. The S6 segment, including Met1549, is virtually completely conserved (highlighted in yellow) among orthologs and all paralogs
that are activated by small changes in membrane potential (l, low voltage-activated) but not those activated by large changes (h, high voltage-activated).
M1549 is part of the Met-Phe-Val sequence that is implicated in rapid channel inactivation (Marksteiner et al., 2001).
DOI: 10.7554/eLife.06315.003
The following source data and figure supplements are available for figure 1:
Source data 1. Source data corresponding to Figure 1.
DOI: 10.7554/eLife.06315.004
Figure supplement 1. Cohort population structure by principal component analysis (PCA).
DOI: 10.7554/eLife.06315.005

available for further analysis of transmission (Figure 1). Analysis of kinship coefficients using SNP
genotypes of affected subjects from Illumina Human 1M-Quad beadchips and the KING algorithm
(Manichaikul et al., 2010) provided no evidence that these three kindreds shared recent common
ancestry (Supplementary file 1H, ‘Materials and methods’). Further, haplotypes flanking the CACNA1H
mutation were phased using the BEAGLE program, revealing that the maximum shared haplotype
flanking the CACNA1H mutation among these three kindreds was only 53.6 kb (87.0 kb for the two
European kindreds, Figure 2). From this data, the maximum likelihood estimate of the number of
generations since the last shared common ancestor among these subjects is estimated to be
714 generations 95% CI 290-1268 (Genin et al., 2004). A more conservative analysis identifying
homozygous discordant SNPs (eliminating inference of haplotypes by phasing) still limited the
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Table 1. Clinical features of index cases with CACNA1HM1549V
Subject ID

Gender

Age dx

BP (%ile)

Aldo
(ng/dl)

PRA
(ng/ml/hr)

ARR (ng/dl:
ng/ml/hr)

1347-1

M

3 yrs

160/105 (>99th)

20

<0.1

>200

1390-1

F

7 yrs

150/90 (>99th)

66

0.2

330

1368-1

M

8 yrs

140/90 (>99th)

20

<0.2

>100

333-2

M

9 yrs

192/144 (>99th)

40

<0.7

>57

1393-1

M

2 mos

170/110 (>99th)

87

<0.6

>145

M, male; F, female; age dx, age at diagnosis of hypertension; yrs, years; mos, months; BP, blood pressure; (%ile),
percentile adjusted for age and gender; Aldo, serum aldosterone; PRA, plasma renin activity; ARR, aldosterone:renin
ratio, values >20 with aldosterone level >15 are considered indicative of primary aldosteronism (PA).
DOI: 10.7554/eLife.06315.006

shared haplotype to less than 127.1 kb, consistent with the results of phasing using BEAGLE.
These findings indicate that the CACNA1HM1549V mutation in these three kindreds has not been
inherited from a recent common ancestor, and has either arisen independently or has been
inherited from an extremely remote common ancestor. The latter possibility is extremely unlikely
given the absence of this mutation in more than 129,000 alleles studied to date.
The probability of finding any recurrent protein-altering de novo mutation among 40 kindreds
is ∼4.0 × 10−6 (see ‘Materials and methods’). Even with a conservative estimate of the allele frequency of
CACNA1HM1549V of 0.00001 in the general population (‘conservative’ because it has never been seen
among >129,000 alleles in subjects not selected for early PA), the probability of finding three additional
instances of this mutation in 38 unrelated subjects is ∼8.4 × 10−12. Combined, the probability of finding
these five instances of the identical variant by chance is conservatively estimated to be 3.4 × 10−17,
providing extremely strong statistical support for the role of this mutation in PA.

CACNA1H is expressed in human adrenal glomerulosa
If the CACNA1HM1549V mutation causes early-onset PA, CACNA1H (CaV3.2) should be expressed in
human adrenal glomerulosa. CACNA1H transcripts have previously been reported in human kidney,
liver, heart and brain (Cribbs et al., 1998), and our prior analysis of gene expression of human adrenal
cortex showed that CACNA1H was the second most highly expressed calcium channel alpha subunit,
after CACNA1D (Scholl et al., 2013). We performed immunohistochemistry with two different
antibodies specific for the encoded channel protein (CaV3.2), demonstrating strong staining of
human adrenal glomerulosa; this staining was abolished after preincubation with immunogenic
peptide (Figure 3). These results are consistent with prior in situ hybridization and electrophysiological
studies of rodent and bovine glomerulosa (Schrier et al., 2001; Hu et al., 2012) as well as a recent study
of human adrenal gland (Felizola et al., 2014).

Clinical features of subjects with CACNA1HM1549V variant
The clinical features of the index cases harboring the CACNA1HM1549V variant were uniform.
All presented with hypertension by age 10 and had persistent inappropriate elevation of serum
aldosterone with suppressed PRA and high aldosterone:PRA ratio, indicative of autonomous adrenal
aldosterone production (Table 1). Adrenal imaging by computed tomography, magnetic resonance or
ultrasound showed no evidence of mass or hyperplasia at the time of presentation. There were no
other recurrent or distinctive features of the index cases, specifically no history of seizures, neurologic
or neuromuscular disorders as found in patients with CACNA1D mutations (Scholl et al., 2013).
Additional details are presented in Appendix 1.
By direct Sanger sequencing, we identified five additional CACNA1HM1549V mutation carriers among
family members, including four parents and one uncle of an index case (Figure 1). Of these five, three
were diagnosed with early severe hypertension while two were not, and in fact were normotensive as
adults (Appendix 1 and Supplementary file 1I). For example, subject 1390-2 was diagnosed with severe
hypertension and PA at age 17; her hypertension was difficult to control, leading to unilateral
adrenalectomy at age 29. Her hypertension nonetheless recurred, requiring reinstitution of treatment.

Scholl et al. eLife 2015;4:e06315. DOI: 10.7554/eLife.06315

5 of 22

Research article

Genes and chromosomes | Human biology and medicine

Figure 2. Shared haplotypes in subjects with inherited CACNA1HM1549V variant. Haplotypes of three affected
individuals from kindreds without proven de novo occurrence of CACNA1HM1549V variant were phased using BEAGLE
(‘Materials and methods’) (Browning and Browning, 2007). This analysis identified a very small maximum interval
shared among all three individuals (∼53.6 kb, green box) flanked by rs1075789 and rs3760122. If only homozygous
discordant calls (*) were considered in the absence of phasing, the maximum interval shared by all three subjects
would be 127.1 kb and the longest pairwise shared haplotype would be 200.0 kb between 1393-1 and 333-1.
DOI: 10.7554/eLife.06315.007

Interestingly, the histology of her adrenal gland showed striking microscopic hyperplasia. While the
normal adrenal glomerulosa comprises only a few cell layers and is about 70 μm in depth, the
glomerulosa of subject 1390-2 was ∼30 cell layers and ∼300 μm in depth (Figure 4A–C). CACNA1H
was expressed in the hyperplastic glomerulosa layer (Figure 4, Appendix 1). In this kindred, the
CACNA1HM1549V variant arose concordantly and segregated precisely with PA and early hypertension
(Table 2). Two mutation carriers (1368-2 and 1393-3) were normotensive as adults and had not
been diagnosed as hypertensive in childhood; in subject 1393-3, PRA was at the lower limit of
normal with normal aldosterone level, while PRA and aldosterone levels were normal in 1368-2
(Supplementary file 1I).

Specificity of CACNA1HM1549V variant for early-onset PA
To explore the specificity of this mutation for early-onset PA, we performed targeted Sanger sequencing
for the CACNA1HM1549V variant in germline DNA of 1632 additional unrelated subjects, comprising 324
subjects with PA diagnosed after age 10 years, 96 with hypertension and bilateral adrenal hyperplasia,
and 1212 referred for potential genetic causes of hypertension without evidence of PA. We also
sequenced tumor DNA of 90 APAs, including 40 that did not have mutations in previously implicated
genes (KCNJ5, CACNA1D, ATP1A1, ATP2B3, and CTNNB1 [Choi et al., 2011; Azizan et al., 2013;
Beuschlein et al., 2013; Scholl et al., 2013]). No additional CACNA1HM1549V mutations were identified,
demonstrating striking specificity for early-onset PA.

CACNA1HM1549 lies in a conserved MFV motif
Members of the CaV3 family are activated by small depolarizing changes in the membrane potential
(activation threshold ∼ −60 mV) and display very fast voltage-dependent inactivation (Perez-Reyes,
2003). Methionine at the position corresponding to CACNA1HM1549 is conserved in the S6 helix of repeat
three in all identified orthologs, including invertebrates. In addition, methionine occurs at the paralogous
position in other calcium channels activated by small depolarizing potential changes (Figure 1C).
Prior studies of CaV 3.1 (CACNA1G) have shown that methionine 1549 lies in a methioninephenylalanine-valine (MFV) tripeptide that regulates channel inactivation (Hering et al., 1998;
Marksteiner et al., 2001). Mutation of the homologous methionine in CaV 3.1 to isoleucine or
alanine results in delayed channel inactivation (Marksteiner et al., 2001), and related calcium
channels with isoleucine at the homologous position inactivate more slowly than those with
methionine (Hering et al., 1997) (Figure 1C).
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Figure 3. Immunohistochemistry of CaV3.2 in normal human adrenal gland. Sections of normal human adrenal are
shown. C denotes adrenal capsule; G, glomerulosa; F, fasciculata. (A) Normal adrenal gland stained with
hematoxylin and an antibody to CaV3.2 (Alomone). (B) Higher power image of adrenal in panel (A). (C, D) Absence of
staining after preincubation of the antibody with the antigenic peptide, demonstrating specificity. (E) A second
normal human adrenal gland stained for CACNA1H as in (A, B). (F) Gland from (A–D) stained with a second
α-CACNA1H antibody (Santa Cruz). Scale bars, 100 μm (A, C); 50 μm (B, D, E, F). The results demonstrate expression
of CaV3.2 in the normal zona glomerulosa, which is only several cells in depth.
DOI: 10.7554/eLife.06315.008

CACNA1HM1549V causes loss of normal inactivation
To assess the biophysical properties of CACNA1HM1549V, we heterologously expressed either
CACNA1HWT or CACNA1HM1549V in HEK293T cells and performed whole-cell patch clamp recordings
(Figure 5A). Upon depolarizing voltage steps from −90 mV, CACNA1HWT showed fast activation of
calcium currents followed by rapid inactivation, consistent with prior studies (Cribbs et al., 1998).
In contrast, CACNA1HM1549V exhibited marginally slower activation followed by a dramatically slowed
inactivation. While CACNA1HWT is virtually fully inactivated by 400 ms, CACNA1HM1549V shows strong
tail currents after returning to the holding potential of −90 mV (Figure 5A), demonstrating loss of
normal inactivation, an effect still evident after sustained depolarization for 5 s (Figure 5B).
We fitted mono-exponential equations to the decay phase of the calcium current between −50 mV
and +30 mV. The determined time constants represent the mean time at which the current has
decreased to 1/e of its initial amplitude; the results demonstrate ∼10-fold slower inactivation of
CACNA1HM1549V compared to CACNA1HWT (p < 0.001 at all voltages studied, Figure 5C). In contrast,
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Figure 4. Glomerulosa hyperplasia in adrenal gland of subject 1390-2 with CACNA1HM1549V mutation. C denotes
adrenal capsule; G, glomerulosa; F, fasciculata; R, reticularis; M, medulla. (A) Low power image stained with
hematoxylin and eosin. Scale bar 1000 μm. (B, C) Higher power images of adrenal from panel (A), scale bars 400 μm
(B) or 100 μm (C). The mutant adrenal shows marked zona glomerulosa hyperplasia, with micronodular invasion of
the capsule (denoted by *). (D) Same adrenal gland stained with hematoxylin and antibody to CaV3.2 (Santa Cruz),
demonstrating specific staining of zona glomerulosa. Scale bar, 400 μm. (E, F), higher power images stained with
second antibody to CaV3.2 (Alomone). Scale bars 250 μm (E) or 100 μm (F). CaV3.2 is expressed in the hyperplastic
zona glomerulosa.
DOI: 10.7554/eLife.06315.009

activation and recovery from inactivation were only marginally slower in mutant channels (Figure 5D,
Figure 5—figure supplement 1).

CACNA1HM1549V leads to a shift of activation to less depolarizing
potentials
We also observed a significant shift of activation to less depolarizing potentials (Figure 6). CACNA1HWT
showed half-maximal activation (V1/2 ) at −38.9 ± 1.1 mV (N = 11); in contrast, CACNA1HM1549V showed
V1/2 of −44.2 ± 1.1 mV (N = 11, p = 0.003), resulting in a lower threshold for activation and increase in
size of the ‘window current’, the area under the intersection of activation and inactivation curves
where a fraction of channels are constitutively open. There was no significant effect on single channel
conductance (Figure 6—figure supplement 1).
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Table 2. Laboratory values of carriers and non-carriers of CACNA1HM1549V in kindred 1390
Age
Gender (yrs)

K+
Aldo
PRA
ARR
Direct renin
(mmol/l) (ng/dl) (ng/ml/hr) (Aldo/PRA) (μIU/ml)

Aldo/direct
renin

1390-1

F

15

3.7

37

0.42

88.1

NA

NA

1390-2

F

29

3.5

22

NA

NA

3

7.3

Subject
ID
Carriers

Non-Carriers
1390-4

M

17

4.3

2

1.65

1.2

NA

NA

1390-8

M

37

3.8

<1

2.25

<0.4

NA

NA

1390-5

F

62

4.1

16

18.92

0.8

NA

NA

1390-6

F

51

4.0

4

1.87

2.1

NA

NA

1390-7

F

46

4.3

3

1.67

1.8

NA

NA

M, male; F, female; Age (yrs), Age in years when sample was obtained; K+, serum potassium (reference 3.5–5.5
mmol/l); Aldo, serum aldosterone; PRA; direct renin <5 is indicative of volume-mediated hypertension; ARR,
aldosterone:renin ratio, values >20 (using PRA) or values of aldo/direct renin >2.4 with aldosterone level greater than
15 are considered indicative of PA. Blood samples were drawn on the same day, and values were determined in the
same laboratory (except for 1390-2, in whom values are pre-adrenalectomy at age 29). See Figure 1 for relationships.
1390-6 and −7 are not included in Figure 1, and are sisters of 1390-5.
DOI: 10.7554/eLife.06315.010

Collectively, the changes in inactivation and voltage-dependence of activation cause Ca2+ influx at
membrane potentials close to the resting potential and result in channels that remain open longer,
allowing increased Ca2+ entry.

Discussion
These findings define a previously unrecognized form of PA resulting from a recurrent germline gain
of function mutation in the Ca2+ channel encoded by CACNA1H. The extremely strong statistical
evidence implicating this mutation, its clear gain of function effect, and the known role of Ca2+
signaling on aldosterone production and cell proliferation (Spät and Hunyady, 2004) all strongly
support this conclusion. The effects of this mutation phenocopy the adrenal effects of PA-causing
mutations in KCNJ5 (Choi et al., 2011) and CACNA1D (Scholl et al., 2013), demonstrating a shared
final common pathway by which PA results from increased Ca2+ entry via voltage-gated channels.
These results allow a simple genetic test for this specific cause of severe hypertension and suggest
that inhibition of mutant CACNA1H activity would ameliorate hypertension in patients with this
mutation. While the CACNA1HM1549V mutation explains a significant fraction of the early PA cases, the
causes of the remaining cases in our cohort are still unknown.
There is striking genotype–phenotype correlation among patients with germline and somatic
mutations in KCNJ5 and CACNA1H. Several recurrent germline mutations in KCNJ5 (e.g.,
p.Gly151Arg and p.Thr158Ala) support robust cell proliferation leading to massive adrenal
hyperplasia identifiable on CT scan, leading to adrenalectomy (Choi et al., 2011; Scholl et al.,
2012). In contrast, another recurrent mutation in KCNJ5 (p.Gly151Glu) shows no or minimal
hyperplasia discernable by adrenal imaging (Mulatero et al., 2012; Scholl et al., 2012). While
the former mutations are also found as somatic mutations in about 40% of APAs (Choi et al., 2011;
Mulatero et al., 2012), the latter have not been found in more than 900 APAs (Scholl and Lifton, 2013).
This phenotypic difference is likely accounted for by different effects on Na+ conductance- the germline
mutations that are not associated with APAs or hyperplasia cause markedly greater Na+ conductance,
resulting in very high cell lethality, preventing sustained increases in cell mass (Mulatero et al., 2012;
Scholl et al., 2012). Similarly, adrenal glands with CACNA1HM1549V show little or no hyperplasia by CT
scan and neither this mutation nor other activating mutations in CACNA1H have been seen in APAs. We
have not observed high cell lethality in HEK293T cells expressing CACNA1HM1549V. Germline mutations
that cause massive hyperplasia and somatic mutations that cause APA formation likely require an
optimal Ca2+ signal, one that is high enough to support proliferation but not so high as to cause cell
lethality (Berridge et al., 2000).
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Figure 5. CACNA1HM1549V impairs channel inactivation. Whole-cell patch clamp recordings were performed in
HEK293T cells transfected with CACNA1HWT or CACNA1HM1549V. (A) Cells were held at −90 mV, and voltage steps
between −90 and +50 mV were applied to elicit calcium currents, followed by a step to −90 mV to evoke tail
currents. Representative recordings show rapid activation and inactivation of CACNA1HWT currents and delayed
inactivation of CACNA1HM1549V. Tail currents are exclusively present in CACNA1HM1549V and suggest the presence of
non-inactivated mutant channels at the end of the depolarizing pulse. (B) Tail currents are still present after a 5-s
pulse to −20 mV. The fraction of non-inactivated channels after 5 s was determined by dividing the peak amplitude
at −20 mV before and after 5 s long pulses to voltages between −90 and −20 mV in 5 mV increments
(CACNA1HM1549V: 6.7 ± 1%, N = 12; CACNA1HWT: 2.4 ± 0.5%, N = 9; p = 0.004, protocol not shown in figure).
(C) Exponential fits of the current decay between −50 and +30 mV provide inactivation time constants. Data from
CACNA1HM1549V are shown in blue circles, CACNA1HWT data are shown in red squares. The mutant channel shows
almost 10-fold slower inactivation than wild-type (N = 9 for CACNA1HWT, N = 7–14 for CACNA1HM1549V, p < 0.001
across all voltages studied, Mann–Whitney rank sum test). (D) In contrast, activation time constants at different
voltages are only slightly slower in CACNA1HM1549V compared to WT (cf. ‘Materials and methods’ for details). Source
files are available in Figure 5—source data 1.
DOI: 10.7554/eLife.06315.011
The following source data and figure supplements are available for figure 5:
Source data 1. Source data corresponding to Figure 5.
DOI: 10.7554/eLife.06315.012
Figure supplement 1. Recovery from inactivation is slightly slower in CACNA1HM1549V.
DOI: 10.7554/eLife.06315.013

While germline mutations in KCNJ5 and CACNA1D were discovered following the initial
identification of their somatic mutations in APAs (Choi et al., 2011; Scholl et al., 2013), the discovery of
the recurrent CACNA1H mutation relied entirely on brute force sequencing of patients with early severe
aldosteronism and hypertension. The occurrence of de novo mutations, the reduced penetrance in
adults with the absence of large multiplex families, as well as the absence of distinctive phenotypes that
distinguish these patients from others with early hypertension and aldosteronism, all suggest reasons
that CACNA1H mutations were not previously linked to PA.
The reduced penetrance in adults in particular is interesting—two mutation-carrier parents were
normotensive as adults, without clear evidence of PA. Incomplete penetrance among some carriers of
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mutations that cause aldosteronism (Stowasser
et al., 1995; Mulatero et al., 2002; Scholl et al.,
2013) has been previously described. The explanations for these effects remain unclear, however
age-dependent activity of the renin-angiotensin
system and the ability of older individuals to
modulate dietary salt intake in response to
physiologic demand are potential contributors.
This is well described in the case of heterozygous
loss of function mutation in the receptor for
aldosterone (the mineralocorticoid receptor, MR).
These patients have life-threatening salt-wasting
and volume depletion in the first years of life due
to low signaling through MR, but are asymptomatic as adults. Adult subjects show increased
dietary salt intake and increase MR signaling
by induction of the renin-angiotensin system,
thereby markedly increasing aldosterone levels
(Geller et al., 1998). Other possible mechanisms
for incomplete penetrance include genetic modifiers either in cis or in trans, including the
possibility of somatic mosaicism resulting in
Figure 6. CACNA1HM1549V shifts activation to more absence of the gain of function mutation the
hyperpolarized potentials. (A) Current-voltage plots and
adrenal gland (Youssoufian and Pyeritz,
(B) activation curves show a shift of V1/2 for activation of 2002). While such mosaicism cannot be exthe mutant channel to less depolarizing potentials. The cluded, Sanger sequence traces provided no
voltage dependence of inactivation is shown as open
suggestion of mosaicism in circulating white
circles or squares. For CACNA1HM1549V, the area under
blood cell or saliva DNA (Figure 1A).
the intersection of activation and inactivation curves
CACNA1HM1549V shows constitutive activity at
(where a fraction of channels show continuous activity) is
membrane potentials close to the resting potential,
larger and shifted to more hyperpolarized potentials
allowing channels to be activated despite
compared to CACNA1HWT, allowing for increased
constitutive Ca2+ influx at potentials close to the resting suppression of the renin-angiotensin system
and absence of hyperkalemia. CACNA1HM1549V
potential of zona glomerulosa cells (Hu et al., 2012).
Source files are available in Figure 6—source data 1.
channels also show strikingly delayed inactivaDOI: 10.7554/eLife.06315.014
tion, a finding similar to mechanisms in several
The following source data and figure supplements are
other channelopathies (Cannon et al., 1991;
available for figure 6:
Lerche et al., 1993; Scholl et al., 2013).
Source data 1. Source data corresponding to Figure 6.
In glomerulosa, delayed inactivation is inferred
DOI: 10.7554/eLife.06315.015
to increase the period of membrane potential
Figure supplement 1. CACNA1HM1549V and
depolarizations. Interestingly, recent studies
CACNA1HWT whole-cell current densities and
in mouse have implicated CACNA1H activity
non-stationary noise analysis.
in regular glomerulosa membrane potential
DOI: 10.7554/eLife.06315.016
oscillations that may amplify small changes in
membrane potential to produce significant Ca2+
signals (Hu et al., 2012). Thus this regular activation of CACNA1H, together with a shift of activation
to less depolarized potentials and prolonged activity, provides a mechanism for increased Ca2+
entry, leading to aldosteronism. While a common variant in CACNA1H has been suggested to be
associated with blood pressure in a small genome-wide association study of African American
individuals (Adeyemo et al., 2009), this result did not pass criteria for genome-wide significance,
was only found after exclusion of hypertensive individuals, and was not replicated in larger studies
(International Consortium for Blood Pressure Genome-Wide Association Studies et al., 2011;
Kidambi et al., 2012).
The apparent limitation of the phenotype associated with CACNA1HM1549V to PA with
hypertension despite the expression of CACNA1H in other organs including heart and brain
(Cribbs et al., 1998) is notable, and underscores the challenges in predicting human phenotypes
from knowledge of underlying mutations. No mutation carrier had a history of seizures or cardiac
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arrhythmia. While some prior studies have suggested a role of rare gain of function mutations
in CACNA1H in epilepsy (Chen et al., 2003; Liang et al., 2006; Heron et al., 2007), these
studies have not approached genome-wide levels of significance, do not appear to confer high
risk, and have not been uniformly replicated (Heron et al., 2004; Chioza et al., 2006; Liang
et al., 2006).
Our findings are consistent with evidence supporting a normal role for CACNA1H in the regulation
of human aldosterone biosynthesis (Felizola et al., 2014). Because CACNA1H is activated by small
depolarizing changes in glomerulosa membrane potential, it is likely activated in response to small
day-to-day changes in serum K+ concentration and angiotensin II levels that require fine adjustments
in aldosterone production to maintain volume and electrolyte balance. In contrast, CACNA1D, which
is the most highly expressed calcium channel in adrenal cortex, and which shows larger single channel
conductance than CACNA1H (Michels et al., 2002; Bock et al., 2011), is only activated by large
depolarizations. Activation of this channel likely contributes to the high levels of aldosterone
produced in response to marked volume depletion or hyperkalemia. We suggest that CACNA1H and
CACNA1D act in series in the regulation of aldosterone, with CACNA1H being activated in response
to small, frequent physiologic perturbations and CACNA1D in response to more infrequent large
physiologic challenges.
These findings also raise the question whether inhibition of wild type CACNA1H would lower
blood pressure or aldosterone production. In the general population, loss-of-function variants in
CACNA1H are very rare (cumulative frequency of splice site, frameshift and nonsense variants in the
ExAC database of 0.06%, resulting in expected compound heterozygosity or homozygosity in about
1 in 2.6 million subjects), making such studies challenging. It seems plausible that loss of CACNA1H
could be compensated by activation of the renin-angiotensin system, leading to greater glomerulosa
cell depolarization with consequent activation of CACNA1D, maintaining normal aldosterone
production and blood pressure. Consistent with this suggestion, blood pressure was reportedly
unchanged in a CACNA1H knockout mouse model, although aldosterone levels were not reported
(Chiang et al., 2009). Similarly, selective inhibitors of CACNA1H inhibit aldosterone production in
vitro (Rossier et al., 1998; Perez-Reyes et al., 2009), but do not apparently reduce aldosterone
levels or blood pressure in vivo (Schmitt et al., 1992; Ragueneau et al., 2001). Whether additional
non-dihydropyridine compounds will prove to be more effective in lowering aldosterone levels or
blood pressure will be interesting to assess.

Materials and methods
Subjects
PA was diagnosed based on elevated ARR (>20 ng/dl:ng/ml/hr), typically with aldosterone >15 ng/dl,
or marginally elevated values in the presence of unexplained hypokalemia (Funder et al., 2008).
Venous blood or saliva samples were obtained from subjects with unexplained early-onset PA and
family members. Research protocols were approved by the local institutional review board (IRB), and
informed consent was obtained from all research participants.

DNA preparation, and exome sequencing
DNA was prepared from venous blood or saliva samples using standard procedures. Exome capture
was performed using the 2.1M NimbleGen Exome reagent (Roche NimbleGen, Madison, WI), and 75
base paired end sequencing on the Illumina (San Diego, CA) platform was performed as previously
described (Lemaire et al., 2013). Coverage statistics are provided in Supplementary file 1B.

Sanger sequencing of genomic DNA and genotyping of parent-offspring
trios
Direct bidirectional Sanger sequencing of CACNA1HP1523-R1584 from genomic DNA of indicated
subjects was performed following PCR amplification using primers
CACNA1H_25F (5′-GACCCACCGCCTCTGTG-3′) and CACNA1H_25R (5′-AGCGCCTTACTCCTGCG-3′).
Parent-offspring trios were genotyped as previously described, except for locus D7S820 in kindred
1390 (primers [5′-ATGTTGGTCAGGCTGACTATG-3′] and [5′-GATTCCACATTTATCCTCATTGAC-3′])
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(Scholl et al., 2013). Alleles without known frequencies in the population were omitted from
the analysis.

Immunohistochemistry
Normal human adrenal tissue was obtained from the Yale Pathology archive, and adrenal tissue
from subject 1390-2 from Pathology Services of Beaufort/Charleston (South Carolina, USA).
Immunohistochemistry was performed as previously described (Scholl et al., 2013). Primary
antibodies were α-Ca V 3.2 (#ACC-025, Alomone, Jerusalem, Israel) or T-type Ca++ CP α1H
(SC-25691, Santa Cruz Biotechnology, Santa Cruz, CA), both at dilutions of 1:100; secondary
antibody was donkey α-rabbit (#035-152, 1:500, Jackson, Bar Harbor, ME). For the Alomone
antibody, preincubation with the antigenic peptide (1:1, wt/wt in 10% FBS) was performed for
1 hr at RT. Both antibodies were tested on two independent glands. H&E staining was
performed at Yale Research Histology using routine procedures.

Molecular cloning
Myc-DDK-tagged CACNA1H in pCMV6-Entry was obtained from Origene (Rockville, MD)
(RC212772, NM_021098.2). Site-directed mutagenesis (QuikChange, Agilent Technologies,
Santa Clara, CA) was performed to introduce the p.Met1549Val mutation according to
the manufacturer’s instruction. Each construct was validated by sequencing of the entire
coding region.

Transient transfection and electrophysiological recordings
Culturing of HEK293T cells was performed as described (Scholl et al., 2013). Cells were
transfected with 3 μg of CACNA1HWT or CACNA1HM1549V expression plasmids. For each construct,
two clones were functionally tested. Whole cell patch clamp recordings were performed on
a HEKA EPC10 amplifier (HEKA Elektronik, Ludwigshafen, Germany) as described previously
(Scholl et al., 2013). The extracellular solution contained: 5 mM CaCl2, 125 mM TEA-Cl, 10 mM
HEPES, 15 mM Mannitol, pH 7.4. Pipette solution contained: 100 mM CsCl, 5 mM TEA-Cl, 3.6 mM
PCr-Na2, 10 mM EGTA, 5 mM Mg-ATP, 0.2 mM Na-GTP, 10 mM HEPES, pH 7.4 (titration
with CsOH).
Voltage dependences of activation were determined from the peak current–voltage relation
and fit by a Boltzmann function as described (Marcantoni et al., 2010; Scholl et al., 2013). The
fraction of non-inactivated channels was determined by dividing the peak amplitude at −20 mV
before and after 5 s long pulses to voltages between −90 and −20 mV. Time courses of activation
or inactivation were analyzed by fitting a mono-exponential function (Scholl et al., 2013). The
recovery from inactivation was measured using envelope protocols consisting of an inactivation of
channels during a 5 s pulse to −20 mV followed by holding the membrane potential at −90 for
increasing durations (Coulter et al., 1989). Afterwards, peak currents at −20 mV were measured
and divided by the previous peak current. A plot of these ratios vs the duration of the pulse to −90
mV was fit with a mono-exponential function to obtain time constants for the recovery from
inactivation.
Non-stationary noise analysis was performed as described (Hebeisen and Fahlke, 2005)
using a voltage protocol that activates channels at −20 mV followed by the analysis of the
decay of currents and variance at −90 mV. The initial variance at the holding potential of
−90 mV before activation was regarded as background variance and subtracted from
the recordings. The Lorentzian noise produced by channel opening and closing depends on
the unitary current amplitude (i), the number of channels (N), and the absolute open
probability (P):
σ 2 = N · i 2 · p · ð1 − pÞ:

(1)

Since the macroscopic current amplitude is given by
I = N · p · i;

(2)

the variance-current relationship results in a quadratic distribution:
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The single channel amplitude (i) was derived from the initial slope of a plot of the
variance against the mean isochronal current results. Due to a low open probability (p < 0.5) at
5 mM of external Ca 2+, the recorded data points only described a small part of the
usual parabola and did not allow for determination of the number of channels and open
probabilities.
Data were analyzed in FitMaster (HEKA Elektronik), SigmaPlot (Jandel Scientific, San Rafael, CA)
and Python. Statistical comparisons were performed using Student’s t-test or Mann–Whitney
rank sum test.

Orthologs and paralogs
Proteins encoded by orthologs or close paralogs of CACNA1H in vertebrate and
invertebrate species were identified by a BLAST search. GenBank accessions included
NP_066921.2 (Homo sapiens), O88427.3 (Mus musculus), XP_414830.4 (Gallus gallus),
XP_002932520.2 (Silurana tropicalis), XP_002122425.1 (Ciona intestinalis) and NP_001024496.1
(Caenorhabditis elegans). Human α1 subunit paralogs were as previously described (Scholl
et al., 2013).

Principal component analysis, analysis of relatedness, shared haplotypes
and mutation age
Principal component analysis was performed as previously described (Lemaire et al., 2013).
For analysis of close relatedness, genomic DNA from subjects 333-1, 1347-1, 1368-1, 1390-1,
and 1393-1 was genotyped on Illumina Human 1M-Quad beadchips according to the
manufacturer’s instructions. Data were analyzed using a combination of GenomeStudio
(Illumina) and PLINK v1.07 softwares (Purcell et al., 2007). Mean call rate was 95.7%. Kinship
coefficients were calculated by using the robust algorithm in KING 1.4 (Manichaikul et al.,
2010). For 1393-1, 1368-1 and 333-1, PLINK format was converted to BEAGLE format using
Mega2 (Mukhopadhyay et al., 2005). Haplotypes flanking the CACNA1HM1549V mutation were
phased by observed transmission in kindred 1393 and by maximum likelihood in kindreds 1368
and 333 using BEAGLE v.3.3.2 (Browning and Browning, 2007) and a reference panel (phase 1
1000Genomes project). Only SNPs called in at least two samples were used for imputation, and
only called SNPs were used for determination of the shared interval. Four additional
heterozygous variants in close proximity to CACNA1HM1549V were identified from the 1393-1
exome. For 1368-1 and 333-1, the inferred haplotype producing the largest shared interval was
chosen for further analysis. Mutation age was determined from haplotypes including flanking 41
markers using ESTIAGE (Genin et al., 2004). Recombination fractions were calculated from
marker distances and average recombination rate across the interval (2.9 cM/Mb, deCODE).
Shared allele frequencies were from EUR population (1000 Genomes project), and mutation rate
was set to 2 × 10−8.

Statistical analysis
For statistical analysis, a de novo mutation rate of 1.4 × 10−8 was assumed. The binomial
probability of observing two or more de novo mutations at a specified position in a set of 41
cases (including one affected parent) was calculated and corrected for the target size of the
human exome (24.75 Mb). The likelihood of observing three additional independent mutations
at the identical position in 38 patients was calculated as a binomial probability from the assumed
allele frequency.
The mutation burden per gene in the cohort of patients with PA was compared to that in
a control cohort comprising 724 unaffected parents of patients with congenital heart disease
sequenced to similar depth of coverage on the same exome platform (Zaidi et al., 2013) using
Fisher’s exact test.
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Mane S, Hellman P, Westin G, Åkerström G, Björklund P, Carling T, Fahlke C, Hidalgo P, Lifton RP. 2013. Somatic
and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary
aldosteronism. Nature Genetics 45:1050–1054. doi: 10.1038/ng.2695.
Scholl UI, Lifton RP. 2013. New insights into aldosterone-producing adenomas and hereditary aldosteronism:
mutations in the K+ channel KCNJ5. Current Opinion in Nephrology and Hypertension 22:141–147. doi: 10.1097/
MNH.0b013e32835cecf8.
Scholl UI, Nelson-Williams C, Yue P, Grekin R, Wyatt RJ, Dillon MJ, Couch R, Hammer LK, Harley FL, Farhi A, Wang
WH, Lifton RP. 2012. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the
potassium channel KCNJ5. Proceedings of the National Academy of Sciences of USA 109:2533–2538. doi: 10.
1073/pnas.1121407109.
Schrier AD, Wang H, Talley EM, Perez-Reyes E, Barrett PQ. 2001. alpha1H T-type Ca2+ channel is the
predominant subtype expressed in bovine and rat zona glomerulosa. American journal of Physiology Cell
physiology 280:C265–C272.
Spät A, Hunyady L. 2004. Control of aldosterone secretion: a model for convergence in cellular signaling pathways.
Physiological Reviews 84:489–539. doi: 10.1152/physrev.00030.2003.
Stowasser M, Bachmann AW, Jonsson JR, Tunny TJ, Klemm SA, Gordon RD. 1995. Clinical, biochemical and genetic
approaches to the detection of familial hyperaldosteronism type I. Journal of Hypertension 13:1610–1613.
Stowasser M, Gordon RD, Tunny TJ, Klemm SA, Finn WL, Krek AL. 1992. Familial hyperaldosteronism type II: five
families with a new variety of primary aldosteronism. Clinical and Experimental Pharmacology & Physiology 19:
319–322. doi: 10.1111/j.1440-1681.1992.tb00462.x.
Torpy DJ, Gordon RD, Lin JP, Huggard PR, Taymans SE, Stowasser M, Chrousos GP, Stratakis CA. 1998. Familial
hyperaldosteronism type II: description of a large kindred and exclusion of the aldosterone synthase (CYP11B2)
gene. The Journal of Clinical Endocrinology and Metabolism 83:3214–3218. doi: 10.1210/jcem.83.9.5086.
Youssoufian H, Pyeritz RE. 2002. Mechanisms and consequences of somatic mosaicism in humans. Nature Reviews
Genetics 3:748–758. doi: 10.1038/nrg906.
Zaidi S, Choi M, Wakimoto H, Ma L, Jiang J, Overton JD, Romano-Adesman A, Bjornson RD, Breitbart RE, Brown
KK, Carriero NJ, Cheung YH, Deanfield J, DePalma S, Fakhro KA, Glessner J, Hakonarson H, Italia MJ, Kaltman
JR, Kaski J, Kim R, Kline JK, Lee T, Leipzig J, Lopez A, Mane SM, Mitchell LE, Newburger JW, Parfenov M, Pe’er I,
Porter G, Roberts AE, Sachidanandam R, Sanders SJ, Seiden HS, State MW, Subramanian S, Tikhonova IR, Wang
W, Warburton D, White PS, Williams IA, Zhao H, Seidman JG, Brueckner M, Chung WK, Gelb BD, Goldmuntz E,
Seidman CE, Lifton RP. 2013. De novo mutations in histone-modifying genes in congenital heart disease. Nature
498:220–223. doi: 10.1038/nature12141.

Scholl et al. eLife 2015;4:e06315. DOI: 10.7554/eLife.06315

19 of 22

Research article

Genes and chromosomes | Human biology and medicine

Appendix 1
Case reports
K1347. Subject 1347-1 is a 9-year old male of European ancestry who was diagnosed with
hypertension at age 3 years (blood pressures [BPs] 140–160/90–105 mmHg, >99th percentile).
Evaluation revealed serum aldosterone 12–20 ng/dl, despite completely suppressed plasma
renin activity (PRA) on repeated measures (<0.1 ng/ml/hr); aldosterone:renin ratio (ARR) > 120
to >200 ng/dl:ng/ml/hr. MRI of the abdomen revealed no adrenal or other mass. Further
extensive evaluation for other causes of hypertension was unrevealing. He had normal
echocardiogram, unremarkable serum chemistry including K+ of 3.8 mmol/l (nl 3.3–4.6), normal
renal ultrasound, MR angiogram and computed tomography (CT) angiogram of the renal
vessels, normal urine analysis, thyroid function, 24 hr urinary catecholamines, vanillylmandelic
acid, homovanillic acid, metanephrines, unremarkable evaluation for congenital adrenal
hyperplasia and normal urinary free 18-hydroxy cortisol. The subject was developmentally
delayed (walked at age 14 months, spoke at age >2 years) and received physical and
occupational therapy in early childhood. Neither parent was hypertensive, and there was no
family history of early hypertension, cerebral hemorrhage, stroke or intracranial aneurysm. PRA
remained low on treatment with spironolactone and isradipine, and BP was difficult to control.
On atenolol, amlodipine and amiloride, he continued to have suppressed PRA, and
aldosterone was normal to elevated. His blood pressure is currently well controlled on triple
antihypertensive therapy with eplerenone, amlodipine, and chlorthalidone.
K1390. Subject 1390-1 is a 15-year old African American female. She was born prematurely at
28 weeks gestational age following a pregnancy complicated by maternal pre-eclampsia and
prolonged rupture of membranes (birth weight 1331 g, length 38 cm, head circumference 28
cm, appropriate for gestational age). She developed respiratory distress, bradycardia, mild
pulmonary artery branch stenosis, hyperbilirubinemia and necrotizing enterocolitis that
responded to medical management. Developmental milestones were reported to be normal.
At age 6 years, she was diagnosed with asthma and seasonal allergies. At age 7 years, she
presented with headache, blurry vision and hyperactivity, and was diagnosed with hypertension
(BP 150/90 mmHg, >99th percentile). Evaluation was remarkable for primary aldosteronism with
elevated serum aldosterone (66 ng/dl) and suppressed PRA of 0.2 ng/ml/hr (ARR 330 ng/dl:ng/
ml/hr). No adrenal masses or hypertrophy were observed on CT imaging. Renal ultrasound and
echocardiography were normal. Follow up revealed hypokalemia (serum K+ 3.1 mmol/l), serum
aldosterone of 34 ng/dl and PRA of 0.3 ng/ml/hr (ARR of 113 ng/dl:ng/ml/hr). Her current
medications include hydrochlorothiazide, lisinopril, montelukast and loratadine. Her current
height is 160 cm (38th percentile), and weight is 68.1 kg (89th percentile). Recent BP off
medication was 165/105 mmHg.
The patient’s family history was remarkable for early severe hypertension in her 38-year old
mother (1390-2) who was diagnosed with hypertension (BP 215/115 mmHg) and hypokalemia at
age 17 years. Two pregnancies were complicated by pre-eclampsia, a third resulted in
a miscarriage following complication from appendicitis. Evaluation for secondary hypertension
was consistent with primary aldosteronism. A CT scan at age 29 years showed mild left adrenal
fullness without discrete adrenal mass. Adrenal venous sampling demonstrated aldosterone:
cortisol ratios of 92 ng/dl:13.8 μg/dl = 6.67 ng/μg on the left side, 11 ng/dl:6.9 μg/dl = 1.59 ng/
μg on the right side and 22 ng/dl:9.7 μg/dl = 2.27 ng/μg in the inferior vena cava. Direct renin
was 3 μIU/ml (<5 suggestive of sodium/volume mediated hypertension).
This subject (1390-2) underwent unilateral adrenalectomy at age 29 years to attempt to mitigate
severe hypertension with PA. Pathology demonstrated a 4.8 × 3.5 × 2 cm (normal 5 cm × 2.5 cm)
specimen weighing 8 g (normal 2.8–5.5 g) (Neville and O’Hare, 1982). There was no
macroscopic nodularity. Histology was significant for marked hyperplasia of the adrenal zona
glomerulosa within a ∼0.1 cm cortex with all cell layers and cell types present. While the normal
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adrenal glomerulosa comprises only a few cell layers and is about 70 μm in depth, the
glomerulosa of subject 1390-2 had ∼30 cell layers and was ∼300 μm in depth (Figure 4A–C).
Clusters and trabeculae of glomerulosa cells infiltrated the fibrous capsule of the gland at
multiple foci, with occasional micronodules just over the capsule. Staining with specific
antibodies demonstrated that CACNA1H was expressed in the hypercellular glomerulosa of
the patient (Figure 4D–F). Consistent with her germline mutation, hypertension recurred after
surgery, requiring reinstitution of treatment. Her current medications are hydrochlorothiazide,
lisinopril and metoprolol succinate, and recent BP on medication was 138/87.
The index case’s father (1390-3), brother (1390-4) and maternal grandfather (1390-10) are
normotensive. While the maternal grandmother (1390-5) was diagnosed with adult-onset
hypertension, her aldosterone was normal (16 ng/dl), with non-suppressed PRA (18.92 ng/ml/hr)
(Table 2).
K1368. Subject 1368-1 is a 19-year old male of European ancestry. His birth weight was 3740 g.
Perinatal history was unremarkable. He underwent pyloromyotomy due to pyloric stenosis at
age 5 weeks, and was hospitalized for respiratory distress at age 7 months. At age 8 years, he
was found to be hypertensive, and evaluation at age 9 years revealed BPs of 130–140/80–90
mmHg (>99th percentile systolic; >95th percentile diastolic). Serum aldosterone was 20 ng/dl,
PRA <0.2 ng/ml/hr (ARR >100 ng/dl:ng/ml/hr), and urinary aldosterone 20 μg/24 hr (nl 2–20).
Renal ultrasound and angiogram at age 9 were unremarkable, and no adrenal enlargement was
noted. On treatment with lisinopril and amlodipine, BP was 120–130/60–65 mmHg at age 13
(>95th percentile systolic, >50th percentile diastolic). Serum K+ was 3.6 mmol/l, and total CO2
was 30 mmol/l. Repeat aldosterone on medication was 5 ng/dl, and PRA was 0.1 ng/ml/hr.
Neurologic evaluation revealed attention deficit disorder, but no medication was started.
Height at age 14 was 157.5 cm (10th percentile), and weight was 41 kg (fifth percentile). BP
further improved to 118/74 mmHg at age 14 (>50th percentile); serum K+ was 3.8 mmol/l and
total CO2 25 mmol/l. After diagnosis of a mild mitral valve prolapse, treatment with a betablocker was started, and amlodipine was discontinued.
The patient’s family history was remarkable for a maternal uncle (1368-4) who was diagnosed
with hypertension at age 24 (BP 200/100 by history). He was treated with hydrochlorothiazide.
At age 51 years, on treatment with 12.5 mg hydrochlorothiazide, his BP was 120/80 mmHg, with
aldosterone 11 ng/dl and PRA 1.2 ng/ml/hr (note that treatment with hydrochlorothiazide
increases PRA), with serum K+ 3.8 mmol/l. The patient’s mother was normotensive, with a home
BP of 116/80 mmHg. There was no evidence of primary aldosteronism (aldosterone 8 ng/dl,
PRA 4.73 ng/ml/hr, serum K+ 3.7 mmol/l. The maternal grandfather reportedly had hypokalemia
and hypertension and a remote history of seizures, which had resolved. He died from
hemorrhagic stroke at age 76 years.
K333. Subject 333-2 is a 35-year old male of European ancestry who was diagnosed with
hypertension at age 9 years (BP 192/144 mmHg) with a history of headaches, enuresis, polyuria
and polydipsia. Retrospectively, a BP of 160/80 prior to surgery for unilateral orchiopexy and left
inguinal hernia repair at age 2 years was noted. Serum K+ was 3.7 mmol/l, Cl− 108 mmol/l (nl
95–105), and other serum electrolytes, creatinine and blood urea nitrogen were normal.
Extensive evaluation including ultrasound, CT scan, angiogram and i.v. pyelogram did not
reveal any renal or adrenal abnormalities. ECG and echocardiogram were normal. Aldosterone
levels were 25 and 40 ng/dl, and renin was suppressed at <0.7 ng/ml/hr. A dexamethasone test
(0.5 mg 4 times a day) did not change BP, but aldosterone after 36 hr decreased to 3.2 ng/dl,
and PRA was 0.3 ng/ml/hr. The subject had normal 24-hr urine vanillylmandelic acid, free
cortisol, 5-OH indoleacetic acid and 17-OH progesterone, serum corticosterone, dehydroepiandrosterone, deoxycorticosterone, progesterone, 17-OH pregnenolone, ACTH and TSH. At
age 17 years, height was 178 cm (78th percentile), and weight was 75 kg (62th percentile).
Treatment with spironolactone, and later minoxidil, atenolol, hydrochlorothiazide, and lisinopril
was initiated. At age 35 years, height was 185 cm, and weight was 109 kg. BP was 124/65
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mmHg, and serum K+ was 3.7 mmol/l on treatment with atenolol, hydrochlorothiazide, lisinopril,
minoxidil, and potassium chloride.
Family history was significant for early-onset hypertension in the subject’s father (333-1), who
was diagnosed with hypertension at age 13 years, but had been hospitalized at age 5 years for
evaluation of precocious puberty, with recorded BPs of 130–160/90–120 mmHg. He has been
on antihypertensive medication since age 19 years. The paternal grandmother was also
reportedly diagnosed with hypertension in her youth.
K1393. Subject 1393-1 is a 5-year old Hispanic male (height 111.8 cm, 72nd %ile, weight 20.9
kg, 82nd %ile). He presented at age 2 months with a viral illness, was admitted to rule out sepsis
and found to be extremely hypertensive (BP 170s/100s mmHg, >99th percentile). Serum K+ was
4.1 mmol/l, Cl− 110 mmol/l, and other electrolytes and creatinine were normal. On
echocardiogram, he had mild left ventricular hypertrophy without coarctation. A renal
angiogram was normal. Aldosterone was elevated at 87.2 ng/dl, and PRA was suppressed at
<0.6 ng/ml/hr. Laboratory evaluation for other causes of hypertension was unrevealing and
included normal thyroid function test, 24-hr urine metanephrines, vanillylmandelic acid,
homovanillylmandelic acid and tests for congenital adrenal hyperplasia. ECG at age 4 years
showed right ventricular conduction delay and prominent mid precordial ventricular forces, and
echocardiogram showed minimal concentric left ventricular hypertrophy without left ventricular
outflow obstruction, systolic or diastolic dysfunction.
Treatment with propranolol, captopril, hydralazine and spironolactone was started, and
aldosterone increased to 290 ng/dl, with renal vein renin <0.6 ng/ml/hr. Current medications
include Enalapril, Spironolactone and Propranolol. There was no known family history of
hypertension. The father (1393-3) had serum of K+ 3.9 mmol/l, low plasma renin of 0.81 ng/ml/hr
and normal aldosterone of 9.3 ng/dl, with BP of 120/82 mmHg.
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